---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004638"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:43:17.923182+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reports FY2022 net loss $248.7M; cash $644.9M; provides clinical updates

## Summary
- Net loss $248.7M for FY2022 vs $187.1M in 2021; Q4 net loss $56.5M.
- Cash, equivalents and securities $644.9M as of Dec 31, 2022; expects to fund operations through 2024.
- Revenue $35.4M in FY2022 includes $7.6M non-cash adjustment from Sanofi collaboration termination.
- RMC-6236 shows early antitumor activity: 12 evaluable patients all stable or better, 10 with tumor reductions, 2 partial responses.
- Sanofi terminates SHP2 collaboration effective June 2023; Revolution regains global rights to RMC-4630.

## SEC filing metadata
- accession: 0000950170-23-004638
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/0000950170-23-004638-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/rvmd-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004638
- JSON: https://secwatch.observer/filing/0000950170-23-004638.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004638.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/0000950170-23-004638-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.